Platelets in Alzheimer's disease-associated cellular senescence and inflammation

Current Pharmaceutical Design

Volumn 19, Issue 9, 2013, Pages 1727-1738

  Casoli, Tiziana ^a   Balietti, Marta ^a   Giorgetti, Belinda ^a   Solazzi, Moreno ^a   Scarpino, Osvaldo ^a   Fattoretti, Patrizia ^a  

^a INRCA   (Italy)

Author keywords

Aging; Alzheimer's disease; Amyloid; Inflammation; Platelets; Senescence; Therapeutic targets

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CD28 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DONEPEZIL; EBSELEN; GAMMA INTERFERON; HEPARIN; HIGH MOBILITY GROUP B1 PROTEIN; IBUPROFEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PARACETAMOL; RANTES; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APATHY; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CELL INTERACTION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CYTOPLASM; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; ENDOTHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; M PHASE CELL CYCLE CHECKPOINT; MICROGLIA; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TELOMERE SHORTENING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UPREGULATION;

EID: 84876721533     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213805219694     Document Type: Article

References (168)

1. Haigis MC, Yankner BA. The aging stress response. Mol Cell 2010; 40: 333-44.
2. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009; 64: 110-22.
3. Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev 2006; 30: 730-48.
4. Esiri MM. Ageing and the brain. J Pathol 2007; 211: 181-7.
5. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008, 3: 41-66.
6. Bertoni-Freddari C, Fattoretti P, Casoli T, Meier-Ruge W, Ulrich J. Morphological adaptive response of the synaptic junctional zones in the human dentate gyrus during aging and Alzheimer's disease. Brain Res 1990; 517: 69-75.
7. Moller P, Lohr M, Folkmann JK, Mikkelsen L, Loft S. Aging and oxidatively damaged nuclear DNA in animal organs. Free Radic Biol 2010; 48: 1275-85.
8. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. Clin Geriatr Med 2004; 20: 329-59.
9. Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol 2010; 190: 719-29.
10. Foster TC. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 2007; 6: 319-25.
11. Bertoni-Freddari C, Fattoretti P, Casoli T, Spagna C, Meier-Ruge W, Ulrich J. Morphological plasticity of synaptic mitochondria during aging. Brain Res 1993; 628: 193-200.
12. Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem 2008; 106: 24-36.
13. Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosi 2008; 28: 1410-20.
14. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
15. Cristofalo VJ, Pignolo RJ. Replicative senescence of human fibroblast-like cells in culture. Physiol Rev 1993; 73: 617-38.
16. Röhme D. Evidence for a relationship between longevity of mammalian species and life spans of normal fibroblasts in vitro and erythrocytes in vivo. Proc Natl Acad Sci USA 1981; 78: 5009-13.
17. Berry IJ, Burns JE, Parkinson EK. Assignment of two human epidermal squamous cell carcinomas cell lines to more than one complementation group for the immortal phenotype. Mol Carcinog 1994; 9: 134-42.
18. Pera MF, Reubinoff B, Trounson A. Human embryonic stem cells. J Cell Sci 2000; 113: 5-10.
19. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence associated beta-galactosidase (SAbetagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798-806.
20. Afanas'ev I. Superoxide and nitric oxide in senescence and aging. Front Biosci 2009; 14:3899-912.
21. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004; 114: 1299-307.
22. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. Chromosoma 2007; 116: 431-40.
23. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8: 729-40.
24. de Magalhães JP, Chainiaux F, de Longueville F, et al. Gene expression and regulation in H2O2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase. Exp Gerontol 2004; 39: 1379-89.
25. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010; 5: 99-118.
26. Acosta JC, O'Loghlen A, Banito A, Raguz S, Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle 2008; 7: 2956-9.
27. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 2010; 16: 238-46.
28. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-60.
29. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer 2007; 43: 2144-52.
30. Helmbold H, Deppert W, Bohn W. Regulation of cellular senescence by Rb2/p130. Oncogene 2006; 25: 5257-62.
31. Vaziri H, Benchimol S. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. Oncogene 1999; 18: 7676-80.
32. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-4.
33. Castro P, Giri D, Lamb D, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 2003; 55: 30-8.
34. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006; 443: 448-52.
35. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006; 443: 453-7.
36. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4apositive senescent cells delays ageing-associated disorders. Nature 2011; 479: 232-6.
37. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008; 27: 2801-9.
38. Møller P, Løhr M, Folkmann JK, Mikkelsen L, Loft S. Aging and oxidatively damaged nuclear DNA in animal organs. Free Radic Biol Med 2010; 48: 1275-85.
39. Bessis A, Béchade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007; 55: 233-8.
40. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9: 259-70.
41. Streit WJ, Semple-Rowland SL, Hurley SD, Miller RC, Popovich PG, Stokes BT. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 1998; 152: 74-87.
42. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol 1990; 30: 81-93.
43. Moller T, Hanisch UK, Ransom BR. Thrombin-induced activation of cultured rodent microglia. J Neurochem 2000; 75: 1539-47.
44. Streit WJ, Xue QS. Life and Death of Microglia. J Neuroimmune Pharmacol 2009; 4: 371-9.
45. Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 2004; 45: 75-88.
46. Flanary BE, Streit WJ. Telomeres shorten with age in rat cerebellum and cortex in vivo. J Anti-Aging Med 2003; 6: 299-308.
47. Chen Y. Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003; 23: 137-49.
48. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
49. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28: 138-45.
50. Sturrock RR. A morphological study of the neostriatum of aged mice with particular reference to neuroglia. J Hirnforsch 1987; 28: 505-15.
51. Landfield PW, Braun LD, Pitler TA, Lindsey JD, Lynch G. Hippocampal aging in rats: a morphometric study of multiple variables in semithin sections. Neurobiol Aging 1981; 2: 265-75.
52. Nichols NR, Day JR, Laping NJ, Johnson SA Finch CE. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging 1993; 14: 421-9.
53. Porchet R, Probst A, Bouras C, Draberova E, Draber P, Riederer BM. Analysis of glial fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics 2003; 3: 1476-85.
54. Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci 2011; 34: 3-11.
55. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463-77.
56. Terman A. Garbage catastrophe theory of aging: imperfect removal of oxidative damage? Redox Rep 2001; 6: 15-26.
57. Zhu X, Rottkamp CA, Raina AK, et al. Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease. Neurobiol Aging 2000; 21: 807-13.
58. Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci USA 1993; 90: 2074-77.
59. Doetsch F, Alvarez-Buylla A. Network of tangential pathways for neuronal migration in adult mammalian brain. Proc Natl Acad Sci USA 1996; 93:14895-900.
60. van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, Gage FH. Functional neurogenesis in the adult hippocampus. Nature 2002; 415: 1030-4.
61. Kempermann G. Why new neurons? Possible functions for adult hippocampal neurogenesis. J Neurosci 2002; 22: 635-8.
62. Chirumamilla S, Sun D, Bullock MR, Colello RJ. Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. J Neurotrauma 2002; 19: 693-703.
63. Sun D, McGinn MJ, Zhou Z, Harvey HB, Bullock MR, Colello RJ. Anatomical integration of newly generated granule neurons following TBI in adult rats and its association to cognitive recovery. Exp Neurol 2007; 204: 264-72.
64. McGinn MJ, Colello RJ, Sun D. Age-related proteomic changes in the subventricular zone and their association with neural stem/progenitor cell proliferation. J Neurosci Res 2012; 90: 1159-68.
65. Cameron HA, Hazel TG, McKay RD. Regulation of neurogenesis by growth factors and neurotransmitters. J Neurobiol 1998; 36: 287-306.
66. Borenstein, In: Neuroepidemiology. From Principles to Practice. USA: Oxford University Press 2004.
67. Fernández M, Gobartt AL, Balañá M, COOPERA Study Group. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 2010; 10: 87.
68. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006171.
69. Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med 2010; 77: 32-42.
70. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1: a006189.
71. Buoso E, Lanni C, Schettini G, Govoni S, Racchi M. Beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 2010; 62: 308-17.
72. Larson ME, Lesné SE. Soluble Aβ oligomer production and toxicity. J Neurochem 2012; 120 (Suppl 1): 125-39.
73. Kuperstein I, Broersen K, Benilova I, et al. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010; 29: 3408-20.
74. Yew DT, Li WP, Webb SE, Lai HW, Zhang L. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp Gerontol 1999; 34: 117-33.
75. Reddy PH, Beal MF. Amyloid Beta, Mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 2008; 14: 45-53.
76. Wang B, Wang J, Zhou S, et al. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci 2008; 268: 172-5.
77. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993; 43: 192-7.
78. Desikan RS, Sabuncu MR, Schmansky NJ, et al. Alzheimer's Disease Neuroimaging Initiative. Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One 2010; 5: e12853.
79. Holtzman DM, Herz J, Bu G. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006312.
80. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-22.
81. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17: 79-89.
82. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006213.
83. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012; 8: 65-73.
84. Allain H, Bentué-Ferrer D, Tribut O, Gauthier S, Michel BF, Drieu-La Rochelle C. Alzheimer's disease: the pharmacological pathway. Fundam Clin Pharmacol 2003; 17: 419-28.
85. Racchi M, Mazzucchelli M, Porrello E, Lanni C, Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 2004; 50: 441-51.
86. Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother 2011; 11: 1359-70.
87. Giulian D, Haverkamp LJ, Yu JH Karshin W, et al. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 1996; 16: 6021-37.
88. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17: 2284-94.
89. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
90. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27: 1-8.
91. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-68.
92. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 2009; 11: 59-98.
93. Passos JF, Von Zglinicki T: Oxygen free radicals in cell senescence: are they signal transducers? Free Radic Res 2006; 40: 1277-83.
94. Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res 2007; 10: 61-74.
95. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated betagalactosidase assay. Methods Mol Biol 2007; 371: 21-31.
96. Korotzer AR, Pike CJ, Cotman CW. Beta-amyloid peptides induce degeneration of cultured rat microglia. Brain Res 1993; 624: 121-5.
97. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 2004; 77:1-8.
98. Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci 2006; 29: 506-10.
99. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009; 118: 75-85.
100. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971: 197-209.
101. Pertusa M, García-Matas S, Rodríguez-Farré E, Sanfeliu C, Cristòfol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J Neurochem 2007; 101: 794-805.
102. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2008; 19: 392-8.
103. Lee HG, Casadesus G, Zhu X, et al. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int 2009; 54: 84-8.
104. Ueberham U, Arendt T. The expression of cell cycle proteins in neurons and its relevance for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005; 4: 293-306.
105. Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G. To die or not to die: that is the autophagic question. Curr Mol Med 2008; 8: 78-91.
106. Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64: 113-22.
107. Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy: a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171: 87-98.
108. Pickford F, Masliah E, Britschgi M. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008; 118: 2190-9.
109. Song DK, Im YB, Jung JS, Cho J, Suh HW, Kim YH. Central betaamyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem 2001; 76: 1326-35.
110. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 2003; 38: 833-41.
111. Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: Tcell senescence and contraction of T-cell repertoire diversity-catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther 2003; 5: 225-34.
112. Young NT, Uhrberg M. KIR expression shapes cytotoxic repertoires: a developmental program of survival. Trends Immunol 2002; 23: 71-5.
113. Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002; 105: 570-5.
114. Speciale L, Calabrese E, Saresella M, et al. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 2007; 28: 1163-9.
115. Larbi A, Pawelec G, Witkowski JM, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 2009; 17: 91-103.
116. Xue SR, Xu DH, Yang XX, Dong WL. Alterations in lymphocyte subset patterns and co-stimulatory molecules in patients with Alzheimer disease. Chin Med J (Engl) 2009; 122: 1469-72.
117. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011;186: 1809-15.
118. Panossian LA, Porter VR, Valenzuela HF, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003; 24: 77-84.
119. Grodstein F, van Oijen M, Irizarry MC, et al. Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study. PLoS One 2008; 3: e1590.
120. Hochstrasser T, Marksteiner J, Humpel C. Telomere length is agedependent and reduced in monocytes of Alzheimer patients. Exp Gerontol 2012; 47: 160-3.
121. Effros RB, Zhu X, Walford RL. Stress response of senescent T lymphocytes: reduced hsp70 is independent of the proliferative block. J Gerontol 1994; 49: 65-70.
122. Effros RB. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Compar Immunol 1997; 21: 471-8.
123. Adibzadeh M, Pohla H, Rehbein A, Pawelec G. Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? Mech Ageing Dev 1995; 83: 171-83.
124. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNF-alpha plus IFN-gamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-8.
125. Wisniewski HM, Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol 1994; 87: 233-41.
126. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid betapeptide is produced by cultured cells during normal metabolism. Nature 1992; 359: 322-5.
127. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998; 153: 725-33.
128. Kokjohn TA, Van Vickle GD, Maarouf CL, et al. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 2011; 1812: 1508-14.
129. Perlmutter LS. Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol 1994; 9: 33-40.
130. Piletz JE, Sarasua M, Whitehouse P, Chotani M. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging 1991; 12: 401-6.
131. Parker WD, Mahr NJ, Filley CM, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 1994; 44: 1086-90.
132. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1995; 9: 213-7.
133. Padovani A, Borroni B, Colciaghi F, et al. Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. Mech Ageing Dev 2001; 122: 1997-2004.
134. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a biomarker for Alzheimer's disease. J Neurol Sci 2006; 240: 53-58.
135. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease Ab amyloid peptide by activated human platelets. Lab Invest 1998; 78: 461-9.
136. Casoli T, Di Stefano G, Giorgetti B, et al. Platelet as a physiological model to investigate apoptotic mechanisms in Alzheimer betaamyloid peptide production. Mech Ageing Dev 2008; 129: 154-62.
137. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55: 530-6.
138. Casoli T, Di Stefano G, Balietti M, Solazzi M, Giorgetti B, Fattoretti P. Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. Biogerontology 2010; 11: 627-33.
139. Klinger MH. Platelets and inflammation. Anat Embryol (Berl) 1997; 196: 1-11.
140. Bermejo P, Martín-Aragón S, Benedí J, et al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008; 117: 198-202.
141. Giri R, Shen Y, Stins M, et al. Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 2000; 279: C1772-C81.
142. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 1998; 807: 107-10.
143. Hartley PS. Platelet senescence and death. Clin Lab 2007; 53: 157-66.
144. Pereira J, Soto M, Palomo I, et al. Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 2002; 87: 905-9.
145. Rand ML, Wang H, Bang KW, Poon KS, Packham MA, Freedman J. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost 2004; 2: 651-9.
146. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res 2006; 28: 630-6.
147. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Platelet protease nexin-2/amyloid beta-protein precursor. Possible pathologic and physiologic functions. Ann N Y Acad Sci 1991; 640: 140-4.
148. Wisniewski HM, Wegiel J, Vorbrodt AW, Mazur-Kolecka B, Frackowiak J. Role of perivascular cells and myocytes in vascular amyloidosis. Ann N Y Acad Sci 2000; 903: 6-18.
149. Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 2001; 22: 837-42.
150. Townsend KP, Obregon D, Quadros A, et al. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann N Y Acad Sci 2002; 977: 65-76.
151. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 2003; 62: 1287-301.
152. Golde TE, Miller VM. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther 2009; 1: 5.
153. Webber KM, Raina AK, Marlatt MW, et al. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech Ageing Dev 2005; 126: 1019-25.
154. Webber KM, Casadesus G, Zhu X, et al. The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Des 2006; 12: 691-7.
155. Zhang ZH, Ouyang Q, Gan HT. Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells. World J Gastroenterol 2004; 10: 2954-57.
156. Woo DH, Han IS, Jung G. Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway. Life Sci 2004; 75: 2439-49.
157. Huguenin S, Fleury-Feith J, Kheuang L, et al. Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 2004; 61: 132-141.
158. Sortino MA, Frasca G, Chisari M, et al. Novel neuronal targets for the acetylcholinesterase inhibitor donepezil. Neuropharmacology 2004; 47: 1198-204.
159. Casadesus G, Zhu X, Atwood CS, et al. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2004; 3: 281-5.
160. Minamino T, Miyauchi H, Yoshida T, Tateno K, Komuro I. The role of vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr Vasc Pharmacol 2004; 2: 141-8.
161. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091-104.
162. Wojcicki J, Rozewicka L, Barcew-Wiszniewska B, et al. Effect of selenium and vitamin E on the development of experimental atherosclerosis in rabbits. Atherosclerosis 1991; 87: 9-16.
163. Brodsky SV, Gealekman O, Chen J, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 2004; 94: 377-84.
164. Bode-Böger SM, Martens-Lobenhoffer J, Täger M, Schröder H, Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun 2005; 334: 1226-32.
165. Yi TN, Zhao HY, Zhang JS, Shan HY, Meng X, Zhang J. Effect of aspirin on high glucose-induced senescence of endothelial cells. Chin Med J (Engl). 2009; 122: 3055-61.
166. Ma Q, Cornelli U, Hanin I, et al. Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr Pharm Des 2007; 13: 1607-16.
167. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561-4.
168. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging 2002; 23: 531-6.